La vendita allo scoperto per PTC dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di PTC. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

PTC (NASDAQ:PTC) Azioni, Report sulle vendite allo scoperto

PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).

PTC Inc

PT CHANDRA ASRI U/ADR by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

PURETECH HEALTH PLC ORD by PureTech Health PLC

PureTech Health PLC

PetroGas Co

Petrocorp Inc

PTC Therapeutics Inc

PT WILMAR CAHAYA INDNSIA by PT Wilmar Cahaya Indonesia TBK

PARADE TECHS LTD SP/GDR by Parade Technologies Ltd.

Parade Technologies Ltd

In the latest quarter, 6 analysts provided ratings for PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for PTC, revealing an average target of $201.0, a high estimate of $226.00, and a low estimate of $182.00. This upward trend is evident, with the current average reflecting a 2.2% increase from the previous average price target of $196.67.
<img src="https://www.benzinga.com/files/images/story/2024/1729598457_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of PTC by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$226.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$206.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$182.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to PTC. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PTC compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of PTC's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of PTC's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PTC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PTC analyst ratings.</a>
<h2>Unveiling the Story Behind PTC</h2>
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).
<h3>Financial Milestones: PTC's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: PTC's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -4.37%. This indicates a decrease in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: PTC's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.3% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): PTC's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.32%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): PTC's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.12%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.66, PTC faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Critical Insights From PTC Analyst Ratings: What You Need To Know

Baird analyst Joe Vruwink maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $216 to $226.

News

Price Target

Baird Maintains Outperform on PTC, Raises Price Target to $226

Oppenheimer has initiated coverage on Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>), a clinical-stage biotechnology company focused on developing treatments <a target="_blank" href="https://www.benzinga.com/quote/LRMR" rel="noreferrer noopener">for rare diseases</a>.
The analysts view the company&#8217;s lead program, Nomlabofusp, as a differentiated, disease-modifying therapy that targets the key pathogenic mechanism of frataxin (FXN) deficiency in Friedreich&#8217;s ataxia (FA).
Lower FXN levels predict early onset, disease severity, and faster progression.
Friedreich&#8217;s ataxia is a rare neurodegenerative disease affecting ~20,000 patients globally.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38949290/larimar-therapeutics-friedreichs-ataxia-investigational-drug-differentiated-from-bi" rel="noreferrer noopener">Larimar Therapeutics&#8217; Friedreich&#8217;s Ataxia Investigational Drug Differentiated From Biogen&#8217;s Marketed Drug</a>.
Oppenheimer expects open-label extension (OLE) interim data in the fourth quarter of 2024.
Larimar intends to expand into the pediatric population and pursue accelerated approval with a potential FDA marketing application submission in the second half of 2025 under the FDA&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40215310/larimar-therapeutics-reports-second-quarter-2024-operating-and-financial-results" rel="noreferrer noopener">START Pilot Program</a>.
Oppenheimer has initiated with an Outperform rating and a <a href="https://www.benzinga.com/quote/LRMR/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $26</a>.
The analysts assume a 60% chance of accelerated approval, modeling the U.S. launch in 2027 and the European launch in 2028 for FA, estimating $1.2 billion in global revenues in 2030.
Following early 2023 approval, Skyclarys, developed by Reata and acquired by Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) for $7.3 billion in 2023, has generated ~$278 million <a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33440534/biogen-bolsters-rare-disease-portfolio-agrees-to-buy-reata-pharmaceuticals-with-enterprise-value-" rel="noreferrer noopener">in global sales</a>.
Oppenheimer says that Nomlabofusp stands out from its competitors due to its potential to modify the disease.
Although Reata/Biogen&#8217;s Skyclarys has received approval for patients aged over 16 with FA and PTC Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) vatiquinone is approved for patients over 7, Larimar&#8217;s strategy to include pediatric and adolescent FA patients in its Phase 2 OLE trial enables it to address a larger patient demographic and tackle the progressive aspects of the disease.
Price Action: LRMR stock is up 2.56% at $7.61 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41364884/why-aspen-aerogels-shares-are-seeing-blue-skies-on-wednesday" target="_blank" rel="noreferrer noopener">Why Aspen Aerogels Shares Are Seeing Blue Skies On Wednesday</a>.</li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Initiation

Movers

Trading Ideas

General

BIIB

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Rosenblatt analyst Blair Abernethy maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Buy and maintains $195 price target.

Rosenblatt Maintains Buy on PTC, Maintains $195 Price Target

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 6.25% on an annualized basis producing an average annual return of 18.13%. Currently, PTC has a market capitalization of $21.42 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 10 years ago, it would be worth $525.56 today based on a price of $178.30 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728489621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In PTC 10 Years Ago Would Be Worth Today

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.76% on an annualized basis producing an average annual return of 17.1%. Currently, PTC has a market capitalization of $21.65 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 10 years ago, it would be worth $479.45 today based on a price of $180.23 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727796662_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today

Collaboration to Drive PTC's Onshape Initiatives Including Discovery Program, Onshape AI Advisor, and CAD and PDM Conversion Tools
BOSTON, Sept. 25, 2024 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262786-1&amp;h=1683162161&amp;u=https%3A%2F%2Fwww.ptc.com%2F&amp;a=PTC">PTC</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) today announced entry into a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to accelerate the growth of its Onshape&#xAE; cloud-native computer-aided design (CAD) and product data management (PDM) solution. This collaboration will focus on advancing Onshape product enhancements, customer adoption programs, and artificial intelligence (AI) initiatives, all of which are aimed at helping product designers and engineers create new, high-quality products faster and more efficiently.

PTC Announces Strategic Collaboration Agreement With AWS To Help Companies Design Products Faster And Easier With Onshape

Management

PTC Board Appointed Neil Barua To Dual Positions Of President And Chief Executive Officer Of Co

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.15% on an annualized basis producing an average annual return of 15.87%. Currently, PTC has a market capitalization of $20.86 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 10 years ago, it would be worth $432.75 today based on a price of $173.62 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725465616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In PTC 10 Years Ago Would Be Worth This Much Today

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.39% on an annualized basis producing an average annual return of 16.21%. Currently, PTC has a market capitalization of $21.16 billion. 
Buying $1000 In PTC: If an investor had bought $1000 of PTC stock 10 years ago, it would be worth $4,500.00 today based on a price of $176.17 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724268622_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In PTC 10 Years Ago Would Be Worth Today

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.79% on an annualized basis producing an average annual return of 16.28%. Currently, PTC has a market capitalization of $20.14 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 10 years ago, it would be worth $449.24 today based on a price of $168.16 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722958219_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning PTC Stock In The Last 10 Years

In the preceding three months, 4 analysts have released ratings for PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $192.25, along with a high estimate of $202.00 and a low estimate of $182.00. No alteration is observed as the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1722546028_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive PTC is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$182.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Matthew Broome</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to PTC. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of PTC compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of PTC's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of PTC's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PTC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PTC analyst ratings.</a>
<h2>Delving into PTC's Background</h2>
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).
<h3>Unraveling the Financial Story of PTC</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining PTC's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.23% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: PTC's net margin is impressive, surpassing industry averages. With a net margin of 18.98%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): PTC's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): PTC's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.83%, the company may face hurdles in achieving optimal financial performance.
Debt Management: PTC's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.74, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMO Capital analyst Daniel Jester maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $200 to $206.

BMO Capital Maintains Outperform on PTC, Raises Price Target to $206

Piper Sandler analyst Clarke Jeffries maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Neutral and raises the price target from $177 to $182.

Piper Sandler Maintains Neutral on PTC, Raises Price Target to $182

Rosenblatt analyst Blair Abernethy maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Buy and raises the price target from $190 to $195.

Rosenblatt Maintains Buy on PTC, Raises Price Target to $195

Guidance

PTC Sees FY24 Adj. EPS $4.85-$5.21 Vs $4.92 Est.; Revenue $2.27B-$2.32B Vs $2.306B Est.

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.96 by 2.08 percent. The company reported quarterly sales of $519.000 million which missed the analyst consensus estimate of $533.536 million by 2.72 percent. This is a 4.30 percent decrease over sales of $542.342 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

PTC Q3 2024 Adj. EPS $0.98 Beats $0.96 Estimate, Sales $519.000M Miss $533.536M Estimate

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.92% on an annualized basis producing an average annual return of 16.61%. Currently, PTC has a market capitalization of $20.96 billion. 
Buying $100 In PTC: If an investor had bought $100 of PTC stock 10 years ago, it would be worth $460.40 today based on a price of $175.04 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721410215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WIIM

AZPN

DDOG

GTLB

HUBS

IREN

Shares of software companies may be trading lower amid a possible selloff following recent strength in the sector.

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 5 years by 2.32% on an annualized basis producing an average annual return of 15.48%. Currently, PTC has a market capitalization of $22.03 billion. 
Buying $1000 In PTC: If an investor had bought $1000 of PTC stock 5 years ago, it would be worth $2,026.77 today based on a price of $183.97 for PTC at the time of writing.
<h3>PTC's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720107017_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

Autodesk: Free Cash Flow Uncertainty And Activist Investor Involvement Creates Opportunity

Stocks with the highest consensus of expected ROE growth, Goldman Sachs says

Hartford MidCap Fund Q2 2024 Commentary

Check Point, CyberArk, among cybersecurity names viewed favorably at Barclays

RBC Capital analyst Matthew Hedberg maintained a Buy rating on PTC (PTC – Research Report) yesterday and set a price target of $202.00. The company...

PTC (PTC): New Buy Recommendation for This Technology Giant

Loop Capital Markets analyst Yun Kim maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $220.00. The company's ...

New Buy Rating for PTC (PTC), the Technology Giant

Bullish Software stocks you shouldn't sleep on

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on PTC (PTC – Research Report) and Adobe (ADBE – Resear...

Analysts' Top Technology Picks: PTC (PTC), Adobe (ADBE)

PTC Is Temporarily Overvalued, Despite A Strong SaaS Transition

Baird raised the firm's price target on PTC (PTC) to $226 from $216 and keeps an Outperform rating on the shares. The firm said partner checks sugg...

PTC price target raised to $226 from $216 at Baird

ADBE

ADSK

ALKT

ANSS

APLS

APTV

AVGO

AVPT

CHKP

CTRA

CYBR

DASTY

DKNG

DOCU

DXCM

ESTC

EXAS

FSLR

GILD

IGPT

INTA

MPWR

NFLX

NWSA

PCOR

PEGA

QRVO

QTWO

SMCI

SNPS

TEAM

TENB

TMUS

TRGP

TSLA

UBER

VEEV

VRNS

ZBRA

Press Releases

PTC to Announce Fiscal Q3'24 Results on Wednesday, July 31st, 2024

PTC ANNOUNCES THIRD FISCAL QUARTER 2024 RESULTS

Cellebrite Appoints Tech Veteran Troy K. Richardson to Board of Directors

PTC Will Participate in Upcoming Investor Conferences

PTC Appoints Rob Bernshteyn to Board of Directors

PTC Announces Strategic Collaboration Agreement with AWS to Help Companies Design Products Faster and Easier with Onshape

Vimeo Appoints Enterprise Software Veteran Charlie Ungashick to Drive Innovation as Chief Marketing Officer

Snyk's AI-Native SAST Product Passes $100M in ARR

PTC to Announce Fiscal Q4'24 Results on Wednesday, November 6th, 2024

CLBT

CLBTW

VMEO

Adobe

Autodesk

Ansys

Applovin Corporation - Class A Common Stock

AppLovin

Aspen Technology

Cadence Design Systems, Inc. - Common Stock

Cadence Design Sys

Salesforce

Datadog

Dynatrace

Fair Isaac

Guidewire Software

HubSpot

Intuit

Samsara

Manhattan Associates, Inc. - Common Stock

Manhattan Associates

MicroStrategy Incorporated - Class A Common Stock

MicroStrategy

Nutanix

Palantir Technologies Inc. Class A Common Stock

Palantir Technologies

Roper Techs

Synopsys

Atlassian Corporation - Class A Common Stock

Atlassian

Tyler Technologies

Workday

Zoom Video Communications, Inc. - Class A Common Stock

Zoom Video Comms

Baird

Rosenblatt

BMO Capital

RBC Capital

Piper Sandler

PAR Technology

Comments

PTC

Vendite allo scoperto

PTC (NASDAQ:PTC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO